Area: Hematology
Location: Orlando, United States
Date: December 5 to December 8
Description:
American Society of Hematology.
Update of Results from the Northstar Study (HGB-204): A Phase 1/2 Study of Gene Therapy for Beta-Thalassemia Major
Safety and Clinical Benefit of Lentiviral Hematopoietic Stem Cell Gene Therapy for Wiscott-Aldrich Syndrome
Lentivector Gene Therapy for X-linked Severe Combined Immune Deficiency in Older Children/Young Adults
Allogeneic T-Cells Expressing an Anti-CD19 Chimeric AR Cause Remissions of B-Cell Malignancies after Allogeneic Hematopoietic SCT
Remissions of Multiple Myeloma during a First-in-Humans Clinical Trial of T Cells Expressing an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor
Genetic Risk Factors for the Development of Osteonecrosis in Children Under Age 10 Treated for ALL
Homozygosity for the 2R Tandem Repeat Polymorphism Is Associated with Increased Risk for Bony Morbidity
Genetic and Response-Based Risk Classification Identifies a Subgroup of NCI High Risk HR B-ALL with Outstanding Outcomes
Genes Influencing the Development and Severity of Chronic ITP Identified through Whole Exome Sequencing
Mercaptopurine (6MP) Intake during Maintenance for Childhood ALL - a Comparison of Self-Report and Electronic Monitoring
Tissue Oxygenation By Transfusion in Severe Anemia with Lactic Acidosis (TOTAL)
Enoxaparin Dose Reduction for Thrombocytopenia in Patients with Cancer: A Quality Assessment Study
Switching to Warfarin after 6-Month Completion of Anticoagulant Treatment for Cancer-Associated Thrombosis
Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia
Hematopoietic SCT from HLA Identical Sibling Forsickle Cell Disease an International Survey
Potent Anti-Sickling Hgb Modifier Reduces Hemolysis, Improves Anemia and Nearly Eliminates Sickle Cells
Novelties in the treatment of AML at ASH 2015
Developments in the treatment of lymphoma
Update in treatment of acute myeloid and acute lymphoblastic leukaemia
Non-Hodgkin lymphoma treatment update at ASH 2015
ASH Annual Meeting Highlights
What is going on in ALL? ASH 2015 update
Novel combinations approved in multiple myeloma